![]() “We will be immediately moving to set aside this excessive and unfounded verdict. “This decision is inconsistent with multiple determinations outside of Philadelphia regarding the adequacy of the Risperdal labeling, the medicine’s efficacy, and findings in support of the company,” Johnson & Johnson said. They also said the plaintiff’s attorneys failed to present any evidence of actual harm. Johnson & Johnson said the court’s exclusion of key evidence left it unable to present a meaningful defense, including what they said was a drug label that “clearly and appropriately outlined the risks associated with the medicine” or Risperdal’s benefits for patients with serious mental illness. Johnson & Johnson said in a statement on its website it was confident that the award would be overturned, calling it “grossly disproportionate” with the initial compensatory damage award and “a clear violation of due process.” There had been settlements as well as verdicts in favor of the plaintiffs. In Philadelphia, about 2,000 plaintiff cases have been filed. Currently, tens of thousands of Risperdal cases are being filed all over the country. ![]() Kline and Itkin said that Johnson & Johnson was “a corporation that valued profits over safety and profits over patients.” Thousands of lawsuits have been filed over the drug, but the attorneys said this was the first in which a jury decided whether to award punitive damages and came up with an amount. Risperdal litigation has been going on for a few years now. They made claims that the drug could help children with psychiatric disorders, such as Attention Deficit Disorder. ![]() ![]() The Risperdal lawsuit claimed the drug was illegally marketed and it was also marketed for off-label uses. Johnson & Johnson used an organized scheme to make billions of dollars while illegally marketing and promoting the drug, attorneys Tom Kline and Jason Itkin said in a statement. In January of 2002, Johnson & Johnson agreed to settle a Medicaid fraud lawsuit for 158 million. ![]()
0 Comments
Leave a Reply. |